bpc 157 fda warning 2024 2025 FDA's Overreach on Compounded Peptides fda warning letter bpc-157 unapproved
Description
It's not worth the risk
Our peptide therapies are carefully selected for their safety, efficacy, and alignment with our clean, wellness-driven philosophy
It acts as a potent inhibitor and blocks the adherence of Staphylococcus aureus to keratinocytes then reduces or prevents skin invasion with this pathogen in order to be effective in human skin infections
These studies suggest it may support tissue repair, promote new blood vessel formation (angiogenesis), and help regulate inflammation
Follow-up Repeat broad markers after 8-12 weeks if symptoms change or the protocol continues
